Study of Interferon-Beta and 5-Fluorouracil for Colorectal Cancer
Author Information
Author(s): JK Joffel, TJ Perren, C Bradley, J Primrose, S Hallam, U Ward, JM lllingworth, PJ Selby
Primary Institution: CRF Cancer Medicine Research Unit, St James's University Hospital
Hypothesis
Does the combination of recombinant interferon-beta and 5-fluorouracil improve treatment outcomes for patients with advanced colorectal carcinoma?
Conclusion
The combination of recombinant human interferon-beta-1 a and 5-fluorouracil is tolerable but does not show a superior response rate compared to previous treatments.
Supporting Evidence
- Four objective responses were seen among 21 evaluable patients.
- The median survival for all patients was 8.4 months.
- Patients who responded to therapy exhibited longer survival.
- The regimen was generally well tolerated with mild toxicities.
Takeaway
Doctors tested a new treatment for colon cancer using two medicines together, but it didn't work better than the old treatment.
Methodology
Patients with advanced colorectal carcinoma were treated with a combination of 5-fluorouracil and recombinant interferon-beta in a non-randomized open phase II study.
Potential Biases
The study was non-randomized, which may introduce selection bias.
Limitations
The study lacked a control group for comparison and had a small sample size.
Participant Demographics
18 males and 9 females, median age 60 years.
Statistical Information
Confidence Interval
95% CI 2-36%
Want to read the original?
Access the complete publication on the publisher's website